PSTV News and Press, PLUS THERAPEUTICS Inc.

Greg Fuller, M.D., Ph.D., former Professor of Pathology (Neuro-Pathology) & Neuro-Radiology at The University of Texas MD Anderson Cancer Center joins Plus as Vice President of Medical Affairs and Medical Director Plus receives notice of an additional $3.3 million CPRIT advance paym...

2024-05-15 21:18:03 ET Plus Therapeutics, Inc. (PSTV) Q1 2024 Earnings Conference Call May 15, 2024 05:00 PM ET Company Participants Marc Hedrick - President and Chief Executive Officer Andrew Sims - Vice President and Chief Financial Officer Norman LaFrance - Se...

2024-05-15 16:22:55 ET More on Plus Therapeutics Plus Therapeutics, Inc. (PSTV) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Plus Therapeutics Historical earnings data for Plus Therapeutics Financial information for Plus Therapeutic...

Announced private placement of up to $19.25M with healthcare funds and insiders Received $3M award recommendation from the Department of Defense to support Plus’ clinical brain cancer program Acquired synergistic leptomeningeal metastases diagnostic portfolio and announce...

Bank of Georgia Group Plc (BDGSF) is expected to report for Q1 2024 iCad Inc. (ICAD) is expected to report for Q1 2024 Yasheng Group (HERB) is expected to report for Q1 2024 Bit Digital Inc. (BTBT) is expected to report $0.01 for Q1 2024 Estrella Immunopharma Inc. (ESLA) is expect...

2024-05-14 17:35:52 ET More on Plus Therapeutics Plus Therapeutics, Inc. (PSTV) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Plus Therapeutics Historical earnings data for Plus Therapeutics Financial information for Plus Therapeutic...

2024-05-14 17:35:24 ET Major earnings expected after the bell on Wednesday include: Cisco Systems ( CSCO ) Grab Holdings Limited ( GRAB ) AST SpaceMobile ( ASTS ) Omeros Corporation ( OMER ) Bit Digital ( BTBT ) Read the full article on Seek...

AUSTIN, Texas, May 13, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announ...

Company acquired assets for the synergistic leptomeningeal metastases (LM) diagnostic platform, “CNSide™ ” and discussed potential partnering opportunities CNSide can significantly improve LM diagnostic accuracy and the market size for Plus’ lead LM radio...

Company acquired all assets for the synergistic CNSide cerebrospinal fluid diagnostic portfolio Company will summarize topline data from the FORESEE clinical trial planned for presentation at the SNO/ASCO Meeting in August 2024 Management call scheduled for Thursday, May 9...